AU2010273642B2 - GPR119 agonists - Google Patents

GPR119 agonists Download PDF

Info

Publication number
AU2010273642B2
AU2010273642B2 AU2010273642A AU2010273642A AU2010273642B2 AU 2010273642 B2 AU2010273642 B2 AU 2010273642B2 AU 2010273642 A AU2010273642 A AU 2010273642A AU 2010273642 A AU2010273642 A AU 2010273642A AU 2010273642 B2 AU2010273642 B2 AU 2010273642B2
Authority
AU
Australia
Prior art keywords
mmol
methanesulfonyl
pharmaceutically acceptable
tetrahydro
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010273642A
Other languages
English (en)
Other versions
AU2010273642A1 (en
Inventor
David Gene Barrett
Ana Belen Bueno Melendo
Jeffry Bernard Franciskovich
Bin Liu
Kumiko Takeuchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43449712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2010273642(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2010273642A1 publication Critical patent/AU2010273642A1/en
Application granted granted Critical
Publication of AU2010273642B2 publication Critical patent/AU2010273642B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
AU2010273642A 2009-07-15 2010-07-12 GPR119 agonists Ceased AU2010273642B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09382114.8 2009-07-15
EP09382114 2009-07-15
US24544509P 2009-09-24 2009-09-24
US61/245,445 2009-09-24
PCT/US2010/041645 WO2011008663A1 (en) 2009-07-15 2010-07-12 Gpr119 agonists

Publications (2)

Publication Number Publication Date
AU2010273642A1 AU2010273642A1 (en) 2012-01-19
AU2010273642B2 true AU2010273642B2 (en) 2014-03-13

Family

ID=43449712

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010273642A Ceased AU2010273642B2 (en) 2009-07-15 2010-07-12 GPR119 agonists

Country Status (24)

Country Link
US (1) US8207344B2 (cg-RX-API-DMAC7.html)
EP (1) EP2454251A1 (cg-RX-API-DMAC7.html)
JP (1) JP5715127B2 (cg-RX-API-DMAC7.html)
KR (1) KR101365854B1 (cg-RX-API-DMAC7.html)
CN (1) CN102471313B (cg-RX-API-DMAC7.html)
AR (1) AR077638A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010273642B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1015921A2 (cg-RX-API-DMAC7.html)
CA (1) CA2764906C (cg-RX-API-DMAC7.html)
CO (1) CO6480977A2 (cg-RX-API-DMAC7.html)
CR (1) CR20120012A (cg-RX-API-DMAC7.html)
DO (1) DOP2012000006A (cg-RX-API-DMAC7.html)
EA (1) EA020540B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP12011606A (cg-RX-API-DMAC7.html)
IL (1) IL216776A0 (cg-RX-API-DMAC7.html)
MA (1) MA33428B1 (cg-RX-API-DMAC7.html)
MX (1) MX2012000704A (cg-RX-API-DMAC7.html)
NZ (1) NZ597125A (cg-RX-API-DMAC7.html)
PE (1) PE20121045A1 (cg-RX-API-DMAC7.html)
SG (1) SG177646A1 (cg-RX-API-DMAC7.html)
TN (1) TN2012000002A1 (cg-RX-API-DMAC7.html)
TW (1) TWI429634B (cg-RX-API-DMAC7.html)
WO (1) WO2011008663A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201200227B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20050532A (sr) 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるgpr119作動薬とddp−iv阻害薬リナグリプチンの組合せ
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
US20140018371A1 (en) * 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US8957062B2 (en) 2011-04-08 2015-02-17 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
WO2012170702A1 (en) * 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
KR101913619B1 (ko) 2011-06-09 2018-12-28 리젠 파마슈티컬스 소시에떼 아노님 Gpr-119의 조절제로서의 신규한 화합물
EP2720544B1 (en) 2011-06-16 2016-12-21 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
WO2013048916A1 (en) * 2011-09-30 2013-04-04 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
EP2771000B1 (en) 2011-10-24 2016-05-04 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as gpr119 agonists
WO2013062835A1 (en) * 2011-10-24 2013-05-02 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as gpr119 agonists
CA2855009C (en) 2011-11-15 2019-07-09 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as gpr119 agonists
WO2013187646A1 (en) * 2012-06-12 2013-12-19 Chong Kun Dang Pharmaceutical Corp. Piperidine derivatives for gpr119 agonist
AU2013290100A1 (en) 2012-07-11 2015-01-29 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
WO2014052619A1 (en) * 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
HUE045926T2 (hu) 2013-11-26 2020-01-28 Chong Kun Dang Pharmaceutical Corp Amid-származékok GPR119 agonistákhoz
KR101651505B1 (ko) * 2014-05-02 2016-08-29 현대약품 주식회사 싸이클로 헥센 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
CA3002540C (en) 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ, インコーポレイテッド S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
JP7397011B2 (ja) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ, インコーポレイテッド S1p1受容体に関連する状態を治療する方法
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009038974A1 (en) * 2007-09-20 2009-03-26 Irm Llc Compounds and compositions as modulators of gpr119 activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20050532A (sr) * 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
EP2059517A1 (en) * 2006-08-30 2009-05-20 Biovitrum AB (publ) Pyrimidine compounds for treating gpr119 related disorders
US7638541B2 (en) * 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009038974A1 (en) * 2007-09-20 2009-03-26 Irm Llc Compounds and compositions as modulators of gpr119 activity

Also Published As

Publication number Publication date
TWI429634B (zh) 2014-03-11
WO2011008663A1 (en) 2011-01-20
MA33428B1 (fr) 2012-07-03
TW201114757A (en) 2011-05-01
NZ597125A (en) 2013-08-30
JP5715127B2 (ja) 2015-05-07
KR20120024964A (ko) 2012-03-14
BRPI1015921A2 (pt) 2016-04-26
CN102471313A (zh) 2012-05-23
KR101365854B1 (ko) 2014-02-21
AU2010273642A1 (en) 2012-01-19
CA2764906A1 (en) 2011-01-20
PE20121045A1 (es) 2012-08-09
ECSP12011606A (es) 2012-02-29
AR077638A1 (es) 2011-09-14
DOP2012000006A (es) 2012-01-31
EA201270169A1 (ru) 2012-06-29
TN2012000002A1 (en) 2013-09-19
US8207344B2 (en) 2012-06-26
SG177646A1 (en) 2012-02-28
CO6480977A2 (es) 2012-07-16
CN102471313B (zh) 2014-06-04
ZA201200227B (en) 2013-06-26
MX2012000704A (es) 2012-03-07
CA2764906C (en) 2014-06-10
IL216776A0 (en) 2012-03-01
EA020540B1 (ru) 2014-11-28
EP2454251A1 (en) 2012-05-23
JP2012533546A (ja) 2012-12-27
US20110015199A1 (en) 2011-01-20
CR20120012A (es) 2012-03-28

Similar Documents

Publication Publication Date Title
US8207344B2 (en) GPR119 agonists
DE602006000339T2 (de) Substituierte pyridinyl und pyrimidinyl derivate als modulatoren eines metabolismus für die behandlung von damit inzusammenhangstehenden krankheiten
JP2023508914A (ja) プロテインチロシンホスファターゼ分解剤及びその使用方法
EP4059929A1 (en) Glp-1 receptor agonist and use thereof
US10023593B2 (en) ALK kinase inhibitor, and preparation method and uses thereof
EP2059517A1 (en) Pyrimidine compounds for treating gpr119 related disorders
TW201835072A (zh) 新穎cyp11a1抑制劑
EA018709B1 (ru) Пиридоновые агонисты сопряженного с g-белком рецептора gpr119
CA2811525A1 (en) Piperidinyl-substituted lactams as gpr119 modulators
JP2013530947A (ja) Gpr119調節薬としてのピペリジニル置換ラクタム
TW201209054A (en) Novel compounds
TW202136271A (zh) 呋喃并吲唑衍生物
EP2693882A1 (en) Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
CA2947552C (en) Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient
TW200526625A (en) Pharmaceutically active compounds
EP2771000B1 (en) Substituted piperidinyl compounds useful as gpr119 agonists
TW201039827A (en) Indoline compound
EP4308096B1 (en) Heteroaroyl amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
TW201938533A (zh) 經脲及苯基取代之哌啶或哌啶酮
WO2013062835A1 (en) Substituted piperidinyl compounds useful as gpr119 agonists
KR101372743B1 (ko) Nk3 수용체 길항제로서 피페리딘 유도체
WO2015167309A1 (ko) 싸이클로 헥센 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
NZ715471A (en) Novel 2,5- or 2,6-disubstituted bicyclic heteroaryl compounds as modulators of gpr-119
NZ715471B2 (en) Novel 2,5- or 2,6-disubstituted bicyclic heteroaryl compounds as modulators of gpr-119

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired